Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

NCT07123779 is registered in ClinicalTrials.gov with 35Pharma Inc as lead sponsor.

NCT NCT07123779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07123779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Lead sponsor
35Pharma Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
January 31, 2030
Enrollment
126 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, pulmonary hypertension